Vera Therapeutics, Inc.
VERA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831828
In the last 90 days, Vera Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 219 institutions reported holding it in 13F filings for Q2 2026, worth $3.34B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Vera Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 1 insider, $4.67M in total
- Insiders trading
- 1
- Net value
- −$4.67M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Vera Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO | 235,244 | Sep 17, 2026 | 8 |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 80,754 | Sep 14, 2026 | 5 |
| Boman Nancy Lee | Chief Regulatory Officer | 44,987 | Aug 5, 2026 | 1 |
| Seidenberg Beth C | Director | 131,553 | May 26, 2026 | 1 |
| Morrissey Michael | Director | – | May 26, 2026 | 1 |
| Enright Patrick G | Director | 5,882 | May 26, 2026 | 2 |
| Meyers James R | Director | – | May 26, 2026 | 2 |
| Morrison Scott W | Director | – | May 26, 2026 | 1 |
| Cheng Andrew | Director | – | May 26, 2026 | 1 |
| Oliger Christy J. | Director | – | May 26, 2026 | 1 |
| Hall Kimball | Director | – | May 26, 2026 | 1 |
| Wright-Mitchell Jane | Chief Legal Officer | 42,403 | Mar 25, 2026 | 1 |
| Hite Christopher | Director | – | Mar 9, 2026 | 1 |
| Johnson David Lee | Chief Operating Officer | 45,727 | Feb 25, 2026 | 2 |
| Turner William D. | Chief Regulatory Officer | 45,313 | Feb 25, 2026 | 5 |
| Grant Sean | CHIEF FINANCIAL OFFICER | 114,181 | Feb 25, 2026 | 2 |
| Brenner Robert | Chief Medical Officer | 50,947 | Feb 25, 2026 | 2 |
| Skelton Laurence Matthew | Chief Commercial Officer | 64,218 | Feb 25, 2026 | 2 |
| Carter Jason S | Chief Legal Officer | 49,136 | Nov 25, 2025 | 1 |
| Katabi Maha | Director | 2,793,987Indirect | May 16, 2025 | 0 |
| Commodore Capital LP | 10% Owner | 4,400,000Indirect | Jan 12, 2024 | 0 |
| Curley Joanne | Chief Development Officer | 26,962 | Aug 23, 2023 | 0 |
| Lin Celia | Chief Medical Officer | 11,010 | Aug 23, 2023 | 0 |
| Tammenoms Bakker Juliet | 10% Owner | 1,714,285Indirect | Feb 8, 2023 | 0 |
| Longitude Venture Partners IV, L.P. | 10% Owner | 1,714,285Indirect | Feb 8, 2023 | 0 |
| Longitude Capital Partners IV, LLC | 10% Owner | 1,714,285Indirect | Feb 8, 2023 | 0 |
| Longitude Prime Partners, LLC | 10% Owner | 1,714,285Indirect | Feb 8, 2023 | 0 |
| Longitude Prime Fund, L.P. | 10% Owner | 1,714,285Indirect | Feb 8, 2023 | 0 |
| Healy James | 10% Owner | 3,467,156 | Feb 8, 2023 | 0 |
| Sofinnova Management X, L.P. | 10% Owner | 3,467,156 | Feb 8, 2023 | 0 |
| Sofinnova Venture Partners X, L.P. | 10% Owner | 3,467,156 | Feb 8, 2023 | 0 |
| Sofinnova Management X-A, L.L.C. | 10% Owner | 3,467,156 | Feb 8, 2023 | 0 |
| TC Group, LLC | 10% Owner | 2,960,231Indirect | Aug 19, 2022 | 0 |
| Carlyle Investment Management LLC | 10% Owner | 2,960,231Indirect | Aug 19, 2022 | 0 |
| Abingworth LLP | 10% Owner | 2,960,231Indirect | Aug 19, 2022 | 0 |
| Carlyle Group Inc. | 10% Owner | 2,960,231Indirect | Aug 19, 2022 | 0 |
| Carlyle Holdings I GP Inc. | 10% Owner | 2,960,231Indirect | Aug 19, 2022 | 0 |
| Carlyle Holdings I GP Sub L.L.C. | 10% Owner | 2,960,231Indirect | Aug 19, 2022 | 0 |
| Carlyle Holdings I L.P. | 10% Owner | 2,960,231Indirect | Aug 19, 2022 | 0 |
| CG Subsidiary Holdings L.L.C. | 10% Owner | 2,960,231Indirect | Aug 19, 2022 | 0 |
| Abingworth Bioventures 8 LP | 10% Owner | 2,960,231Indirect | Aug 19, 2022 | 0 |
| Carlyle Genesis UK LLC | 10% Owner | 2,960,231Indirect | Aug 19, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 12, 2024 (view filing) | Jan 10 | 2 days | Commodore Capital LP10% Owner | SSaleClass A Common Stock | −1.05M | $18.00 | −$18.9M | −19.3%4.40M after | |
| Feb 1, 2024 (view filing) | Jan 30 | 2 days | Katabi MahaDirector | PPurchaseClass A Common Stock | +161.3K | $31.00 | +$5.00M | +4.7%3.63M after | |
| Mar 25, 2024 (view filing) | Mar 21-25 | 4 days | Katabi MahaDirector | SSaleClass A Common Stock | −834.5K | $40.86 | −$34.1M | −23.0%2.79M after | 6 lots |
| Apr 5, 2024 (view filing) | Apr 3 | 2 days | Grant SeanCHIEF FINANCIAL OFFICER | SSaleClass A Common Stock | −99.8K | $39.61 | −$3.95M | −60.1%66.3K after | 4 lots |
| Apr 5, 2024 (view filing) | Apr 3 | 2 days | Grant SeanCHIEF FINANCIAL OFFICER | SSaleClass A Common Stock | −18.6K | $39.42 | −$735.2K | −78.9%5.00K after | 15 lots |
| Apr 12, 2024 (view filing) | Apr 10 | 2 days | Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR | SSaleClass A Common Stock | −5.71K | $40.00 | −$228.6K | −9.7%53.2K after | |
| May 17, 2024 (view filing) | May 15-16 | 2 days | Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR | SSaleClass A Common Stock | −30.8K | $42.30 | −$1.30M | −37.6%51.2K after | 4 lots |
| Aug 16, 2024 (view filing) | Aug 14 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −15.6K | $37.56 | −$586.9K | −4.4%337.1K after | 10b5-1 |
| Aug 23, 2024 (view filing) | Aug 21 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −14.5K | $39.76 | −$575.4K | −4.3%322.7K after | |
| Aug 30, 2024 (view filing) | Aug 28 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −30.3K | $36.84 | −$1.12M | −9.0%308.0K after | 4 lots10b5-1 |
| Sep 13, 2024 (view filing) | Sep 11 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −15.6K | $37.50 | −$586.0K | −4.8%308.0K after | 2 lots10b5-1 |
| Sep 20, 2024 (view filing) | Sep 18-19 | 2 days | Seidenberg Beth CDirector | SSaleClass A Common Stock | −15.0K | $42.29 | −$634.3K | −9.3%146.6K after | 2 lots10b5-1 |
| Sep 20, 2024 (view filing) | Sep 18 | 2 days | Seidenberg Beth CDirector | SSaleClass A Common Stock | −1.48K | $42.00 | −$62.0K | −26.9%4.01K after | 10b5-1 |
| Sep 27, 2024 (view filing) | Sep 25 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −23.1K | $46.05 | −$1.06M | −7.0%308.0K after | 11 lots10b5-1 |
| Oct 11, 2024 (view filing) | Oct 9 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −15.6K | $38.24 | −$597.5K | −4.8%308.0K after | 2 lots10b5-1 |
| Oct 25, 2024 (view filing) | Oct 23 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −19.4K | $40.40 | −$782.7K | −5.9%308.0K after | 4 lots10b5-1 |
| Oct 30, 2024 (view filing) | Oct 28 | 2 days | Seidenberg Beth CDirector | SSaleClass A Common Stock | −15.0K | $48.03 | −$720.5K | −10.2%131.6K after | 2 lots10b5-1 |
| Nov 15, 2024 (view filing) | Nov 13 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −30.6K | $49.50 | −$1.52M | −26.3%85.9K after | 9 lots10b5-1 |
| Nov 27, 2024 (view filing) | Nov 25 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −19.4K | $47.98 | −$929.5K | −18.4%85.9K after | 5 lots10b5-1 |
| Dec 13, 2024 (view filing) | Dec 11 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −17.5K | $46.94 | −$821.5K | −16.9%85.9K after | 4 lots10b5-1 |
| Dec 20, 2024 (view filing) | Dec 18 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −17.5K | $43.07 | −$753.7K | −16.9%85.9K after | 5 lots10b5-1 |
| Jan 10, 2025 (view filing) | Jan 8 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −17.5K | $41.74 | −$730.5K | −10.9%143.6K after | 3 lots10b5-1 |
| Feb 27, 2025 (view filing) | Feb 21-26 | 6 daysLate | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −19.7K | $27.78 | −$546.9K | −8.8%204.7K after | 3 lots10b5-1 |
| Jun 25, 2025 (view filing) | Jun 23-24 | 2 days | Enright Patrick GDirector | PPurchaseClass A Common Stock | +250.0K | $21.11 | +$5.28M | +7.5%3.60M after | 4 lots |
| Nov 13, 2025 (view filing) | Nov 11 | 2 days | Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR | SSaleClass A Common Stock | −15.0K | $29.06 | −$435.9K | −23.9%47.8K after | |
| Nov 25, 2025 (view filing) | Nov 21 | 4 days | Carter Jason SChief Legal Officer | SSaleClass A Common Stock | −3.86K | $27.82 | −$107.5K | −7.3%49.1K after | |
| Dec 4, 2025 (view filing) | Dec 3 | 1 day | Turner William D.Chief Regulatory Officer | SSaleClass A Common Stock | −10.0K | $40.00 | −$400.0K | −30.8%22.5K after | 10b5-1 |
| Dec 10, 2025 (view filing) | Dec 8 | 2 days | Turner William D.Chief Regulatory Officer | SSaleClass A Common Stock | −10.0K | $45.31 | −$453.1K | −30.8%22.5K after | 10b5-1 |
| Dec 15, 2025 (view filing) | Dec 11 | 4 days | Enright Patrick GDirector | PPurchaseClass A Common Stock | +5.88K | $42.50 | +$250.0K | New position5.88K after | |
| Dec 17, 2025 (view filing) | Dec 15 | 2 days | Turner William D.Chief Regulatory Officer | SSaleClass A Common Stock | −10.0K | $50.08 | −$500.8K | −30.8%22.5K after | 10b5-1 |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Johnson David LeeChief Operating Officer | SSaleClass A Common Stock | −2.58K | $41.98 | −$108.3K | −5.3%45.7K after | |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Turner William D.Chief Regulatory Officer | SSaleClass A Common Stock | −2.19K | $41.98 | −$91.8K | −4.6%45.3K after | |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −16.9K | $41.98 | −$710.5K | −6.2%257.2K after | |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR | SSaleClass A Common Stock | −3.12K | $41.98 | −$130.9K | −4.6%64.7K after | |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Grant SeanCHIEF FINANCIAL OFFICER | SSaleClass A Common Stock | −4.95K | $41.98 | −$207.8K | −4.2%114.2K after | |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Brenner RobertChief Medical Officer | SSaleClass A Common Stock | −2.15K | $41.98 | −$90.3K | −4.1%50.9K after | |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Skelton Laurence MatthewChief Commercial Officer | SSaleClass A Common Stock | −1.58K | $41.98 | −$66.4K | −2.4%64.2K after | |
| Apr 15, 2026 (view filing) | Apr 14 | 1 day | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −23.0K | $44.05 | −$1.01M | −8.9%235.2K after | 3 lots10b5-1 |
| Aug 12, 2026 (view filing)6:39 PM ET | May 12 | 92 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −18.5K | $36.74 | −$679.7K | −7.3%235.2K after | Amended2 lots10b5-1 |
| Aug 12, 2026 (view filing)6:41 PM ET | Jun 23 | 50 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −18.5K | $37.93 | −$701.8K | −7.3%235.2K after | Amended2 lots10b5-1 |
| Aug 12, 2026 (view filing)6:42 PM ET | Jul 7 | 36 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −46.3K | $42.30 | −$1.96M | −16.4%235.2K after | Amended4 lots10b5-1 |
| Sep 4, 2026 (view filing)4:15 PM ET | Sep 2 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −18.5K | $35.12 | −$649.6K | −7.3%235.2K after | 10b5-1 |
| Sep 17, 2026 (view filing)4:28 PM ET | Sep 15 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −18.5K | $37.00 | −$684.5K | −7.3%235.2K after | 10b5-1 |